Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NICE recommends MabThera for rheumatoid arthritis
The drug, which is marketed by Roche in the EU, can now be prescribed to patients in England and Wales who have had an inadequate response to or
The drug, which is marketed by Roche in the EU, can now be prescribed to patients in England and Wales who have had an inadequate response to or
Under the terms of the agreement, Forest will pay Daiichi Sankyo an upfront payment of $20 million. Forest will enter into a co-promotion arrangement in the US, providing
The terms of the agreements include a $100 million payment to be made at closing, warrants for the purchase of up to one million shares of the company’s
The study, which included patients with and without depression, also showed greater improvements in patients taking Cymbalta (duloxetine HCl) than in those taking placebo in scores on the
German specialty pharmaceutical company Oncoscience is YM Bioscience’s European partner for the development of nimotuzumab, a humanized EGFR-targeting monoclonal antibody. In the first study, nimotuzumab and the current
The tgAAC09 vaccine candidate utilizes an adeno-associated virus (AAV) vector to deliver genes encoding HIV proteins and is designed to stimulate an immune response against HIV. Modest immune
Enzon is also entitled to receive an additional one-time milestone payment of $15 million in 2012 should certain royalty recognition levels be met for Peg-Intron. A portion of
The agreement grants Schering-Plough exclusive worldwide rights for the development and commercialization of PeriCor’s lead compound, acadesine. Financial terms of the transaction were not disclosed. Acadesine is currently
The company claims that Biferonex is a pH neutral and human serum albumin (HSA) free formulation providing an interferon beta treatment solution for patients suffering from relapsing remitting
In its approvable letter to Solvay Pharmaceuticals, the FDA stated that the company would need to provide additional clinical data and chemistry, manufacturing and controls information prior to